1. SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced today the upcoming presentation of clinical data for the Company's lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be presented as an ePoster at the American Society of Nephrology Kidney Week 2021 Annual Meeting, being held virtually November 4-7, 2021.

    Vera Therapeutics' ePoster session information is as follows:

    Title: Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients
    Session Title: PO1203-3. Glomerular Diseases…

    SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced today the upcoming presentation of clinical data for the Company's lead product candidate, atacicept, from the Phase 2a JANUS clinical trial in patients with IgA nephropathy (IgAN). The data will be presented as an ePoster at the American Society of Nephrology Kidney Week 2021 Annual Meeting, being held virtually November 4-7, 2021.

    Vera Therapeutics' ePoster session information is as follows:

    Title: Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients

    Session Title: PO1203-3. Glomerular Diseases: Treatment and Outcomes

    Abstract Number: PO1638

    Full abstracts will be available on the meeting platform on Friday, October 15, 2021 on a rolling basis. All ePosters will be available on Thursday, November 4, 2021 at 10:00 AM PT and will remain available until Friday, January 7, 2022.

    About Vera

    Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN). For more information, please visit www.veratx.com.

    Contacts

    Investor Contact:

    IR@veratx.com

    Media Contact:

    Greig Communications, Inc.

    Kathy Vincent

    (310) 403-8951

    kathy@greigcommunications.com



    Primary Logo

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced today that it is scheduled to host a key opinion leader (KOL) webinar on IgA Nephropathy (IgAN or Berger's Disease) at 12:00 p.m. ET on Monday, September 20, 2021.

    The event will feature presentations by KOLs Richard Lafayette M.D., Stanford University Medical Center, and Jonathan Barratt, Ph.D., FRCP, University of Leicester. Dr. Lafayette will discuss the rationale for targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) in IgAN. Dr. Barratt will discuss data from trials…

    SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced today that it is scheduled to host a key opinion leader (KOL) webinar on IgA Nephropathy (IgAN or Berger's Disease) at 12:00 p.m. ET on Monday, September 20, 2021.

    The event will feature presentations by KOLs Richard Lafayette M.D., Stanford University Medical Center, and Jonathan Barratt, Ph.D., FRCP, University of Leicester. Dr. Lafayette will discuss the rationale for targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) in IgAN. Dr. Barratt will discuss data from trials targeting BLyS and APRIL in IgAN patients, including the Phase 2a JANUS study of atacicept, which evaluated the efficacy and safety of atacicept in IgAN. Both KOLs will discuss the potential for Vera's atacicept as a treatment option. Atacicept is a recombinant fusion protein that acts as a dual inhibitor of cytokines BLyS and APRIL, which targets B cells and plasma cells, as well as reduces disease-causing autoantibodies.

    Dr. Lafayette and Dr. Barratt will be available to answer questions following their formal presentations.

    To register for the webinar, please click here.

    KOL Biographies

    Richard Lafayette, M.D., is a professor of Medicine (Nephrology) at the Stanford University Medical Center. Dr. Lafayette completed his medical education at New York Medical College and went on to complete his residency at the Long Island Jewish Medical Center, and his fellowship at Stanford University School of Medicine. He is board-certified in Internal Medicine and Nephrology.

    Dr. Lafayette served as the Associate Chair of the Stanford University Department of Medicine from 2002 to 2007, the Clinical Chief of Nephrology at Stanford University from 1999 to 2012, and currently serves as the Director of the Stanford Glomerular Disease Center since 2010. He was honored in America's Top Doctors, Best Doctors from 2004 to 2018, and received America's Top Doctors Award, Castle Connolly Medical Ltd. from 2014 to 2022. Dr. Lafayette has been part of the following boards and professional organizations: Editorial Board, Kidney News, American Society of Nephrology (ASN) (2010 to 2021); Member, Glomerular Disease Advisory Committee, American Society of Nephrology (2013 to 2017); and, Member (ex-officio), Communications Committee, American Society of Nephrology (2015 to Present).

    Jonathan Barratt, Ph.D., FRCP, leads the Renal Research Group within the College of Life Sciences, University of Leicester. Dr. Barratt's research is focused on a bench to bedside approach to improving our understanding of the pathogenesis of IgAN, a common global cause of kidney failure. He is the IgAN Rare Disease Group lead for the United Kingdom National Registry of Rare Kidney Diseases (RaDaR), and a member of the steering committee for the International IgAN Network. He works closely with pharmaceutical companies interested in new treatments for IgAN, is chief investigator for a number of international randomized controlled Phase 2 and 3 clinical trials in IgAN, and was a member of the U.S. Food and Drug Administration and ASN Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgAN Workgroup.

    About Atacicept

    Atacicept is a novel, disease-modifying fully humanized fusion protein that is a dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with immunologic diseases, including IgA nephropathy (IgAN), also known as Berger's disease, and systemic lupus erythematosus. Vera believes that atacicept has the potential to be the best-in-class and the leading B cell-targeted therapy for IgAN. Atacicept has been well tolerated and has been used in clinical trials of more than 1,500 patients to date. In a clinical trial of IgAN patients, data show atacicept is the first known molecule to substantially reduce galactose-deficient immunoglobulin A (Gd-IgA1).

    About Vera

    Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus. For more information, please visit www.veratx.com.

    Forward-looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential of atacicept. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "will", "anticipates," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Vera's business in general, the impact of the COVID-19 pandemic, and the other risks described in Vera's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Contacts

    Investor Contact:

    IR@veratx.com

    Media Contact:

    Greig Communications, Inc.

    Kathy Vincent

    (310) 403-8951

    kathy@greigcommunications.com



    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update.

    "The first half of 2021 was tremendously productive for Vera, during which we achieved key clinical and financial milestones and added great talent to our leadership team, positioning us well to make progress on our business objectives," said Marshall Fordyce, MD, Founder and Chief Executive Officer of Vera Therapeutics. "In the second quarter, we initiated on schedule our Phase 2b clinical trial of atacicept…

    SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update.

    "The first half of 2021 was tremendously productive for Vera, during which we achieved key clinical and financial milestones and added great talent to our leadership team, positioning us well to make progress on our business objectives," said Marshall Fordyce, MD, Founder and Chief Executive Officer of Vera Therapeutics. "In the second quarter, we initiated on schedule our Phase 2b clinical trial of atacicept in patients with IgA nephropathy (IgAN). Known as ‘ORIGIN,' this trial will potentially demonstrate atacicept as the first disease-modifying therapy for patients with IgAN. ORIGIN is a randomized controlled trial powered to determine whether atacicept's proven ability to substantially reduce Gd-IgA1 translates into improvements in renal function, as measured by proteinuria. We look forward to providing additional clinical updates planned for the remainder of 2021 and into 2022."

    Second Quarter and Recent Business Highlights

    • Initiated patient enrollment for the dose-ranging Phase 2b ORIGIN trial, which is evaluating the safety and efficacy of the company's lead product candidate, atacicept, in patients with IgAN who continue to have persistent proteinuria and remain at high risk of disease progression
    • Expanded the management team with several key new hires, including the appointment of Sean Grant, MBA, as Chief Financial Officer to oversee the company's financial operations
    • Reported $91.6 million in cash and cash equivalents as of June 30, 2021, which includes net proceeds from the company's initial public offering, which was completed in the second quarter of 2021

    Financial Results for the Quarter Ended June 30, 2021

    For the three months ended June 30, 2021, the company reported a net loss of $3.4 million, or a net loss per diluted share of $0.33, compared to a net loss of $3.6 million, or a net loss per diluted share of $11.10, for the same period last year. Outstanding shares of redeemable convertible preferred stock were excluded from the computation of net loss per diluted share for periods prior to the conversion of those shares to common stock in May 2021.

    During the six months ended June 30, 2021, net cash used in operating activities was $11.8 million, compared to $5.0 million for the same period last year.

    Vera reported approximately $91.6 million in cash and cash equivalents as of June 30, 2021. This includes approximately $48.4 million in net proceeds from the company's initial public offering of 5,002,500 shares of its Class A common stock, including the underwriters' exercise of their option in full, which was completed in May 2021.

    About Atacicept

    Atacicept is a novel, disease-modifying fully humanized fusion protein that is a dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with immunologic diseases, including IgA nephropathy (IgAN), also known as Berger's disease, and systemic lupus erythematosus. Vera believes that atacicept has the potential to be the best-in-class and the leading B cell-targeted therapy for IgAN. Atacicept has been well tolerated and has been used in clinical trials of more than 1,500 patients to date. In a clinical trial of IgAN patients, data show atacicept is the first known molecule to substantially reduce galactose-deficient immunoglobulin A (Gd-IgA1).

    About Vera

    Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus. For more information, please visit www.veratx.com.

    Forward-looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the results of Vera's Phase 2b ORIGIN trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "will", "anticipates," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Vera's business in general, the impact of the COVID-19 pandemic, and the other risks described in Vera's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Contacts

    Investor Contact:

    IR@veratx.com

    Media Contact:

    Greig Communications, Inc.

    Kathy Vincent

    (310) 403-8951

    kathy@greigcommunications.com



     

    VERA THERAPEUTICS, INC.
    Unaudited Condensed Statements of Operations and Comprehensive Loss
    (in thousands, except share and per share amounts)
              
       Three Months Ended Six Months Ended
       June 30, June 30,
        2021   2020   2021   2020 
    Operating expenses:       
     Research and development$3,235  $1,954  $6,167  $3,393 
     General and administrative 2,614   1,219   4,398   2,251 
    Loss from operations (5,849)  (3,173)  (10,565)  (5,644)
    Total other income (expense) 2,412   (431)  2,414   (434)
    Net loss and comprehensive loss$(3,437) $(3,604) $(8,151) $(6,078)
              
    Net loss per share attributable to common stockholders, basic and diluted

           
    $(0.33) $(11.10) $(1.49) $(18.92)
              
    Weighted-average shares used in computing net loss per share attributable

    to common stockholders, basic and diluted

           
     10,499,937   324,720   5,470,609   321,207 

     





     VERA THERAPEUTICS, INC.   
     Unaudited Condensed Balance Sheets   
     (in thousands)   
              
          June 30, December 31, 
          2021 2020 
     Assets       
     Current assets:      
      Cash and cash equivalents  $91,625  $53,654  
      Restricted cash, current   50   50  
      Prepaid expenses and other current assets   4,201   557  
       Total current assets   95,876   54,261  
     Restricted cash, noncurrent   293   293  
     Non-marketable equity securities   1,478   -  
       Total assets  $97,647  $54,554  
     Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)     
     Current liabilities:      
      Accounts payable  $1,723  $909  
      Restructuring liability, current   360   962  
      Accrued expenses and other current liabilities  1,688   535  
       Total current liabilities   3,771   2,406  
     Restructuring liability, noncurrent   1,435   1,634  
     Accrued and other noncurrent liabilities   286   286  
       Total liabilities   5,492   4,326  
     Redeemable convertible preferred stock   -   139,576  
     Stockholders' equity (deficit)      
      Common stock   21   -  
      Additional paid-in-capital   191,732   2,099  
      Accumulated deficit   (99,598)  (91,447) 
       Total stockholders' equity (deficit)   92,155   (89,348) 
       Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) $97,647  $54,554  
              



    Primary Logo

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Sean Grant, MBA as Chief Financial Officer. In this role, he will oversee all of Vera Therapeutics' financial operations including financial strategy, investor relations, accounting operations, financial planning and analysis, tax, and treasury.

    Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, commented, "We are fortunate to have an executive with Sean's financial acumen and pedigree join our management team at an exciting time for the company…

    SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Sean Grant, MBA as Chief Financial Officer. In this role, he will oversee all of Vera Therapeutics' financial operations including financial strategy, investor relations, accounting operations, financial planning and analysis, tax, and treasury.

    Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, commented, "We are fortunate to have an executive with Sean's financial acumen and pedigree join our management team at an exciting time for the company. His depth and breadth of experience in strategic investments, equity capital markets, and partnerships will be critical as we fulfill our mission to improve medical treatment for patients suffering from serious immunological diseases. On behalf of the entire Vera team, I welcome Sean and look forward to his contributions."



    Sean Grant brings nearly 15 years of multi-disciplinary experience in healthcare and financial services. Mr. Grant joins Vera from CareDx, where he was Vice President of Corporate Strategy and Business Development. During his tenure, he led and directed mergers and acquisitions, venture investments, and partnerships across diagnostics, therapeutics, and digital platforms.

    "I'm excited by the promise of Vera's lead product candidate, atacicept, as we have a unique opportunity to potentially help patients with serious immunological diseases like IgA nephropathy for which there are no disease-modifying medications currently available," said Mr. Grant. "I look forward to partnering with Marshall, the management team, and board to grow the company and fulfill our goal of developing breakthrough medicines for patients with serious immunological diseases."

    Prior to joining CareDx, Mr. Grant served as Vice President in the Investment Banking Healthcare Division at Citigroup. While at Citigroup, he specialized in public and private capital raising as well as M&A and executed a broad range of transactions for many of the world's leading life sciences companies including Gilead, Kite Pharma, and CRISPR Therapeutics. Previous to Citigroup, he held finance, strategy, and business development roles at Piper Jaffray, Grant Consulting, and ESI Group.

    Mr. Grant holds a Master of Business Administration from the Johns Hopkins Carey School of Business and earned his Bachelor of Arts in government and international politics from George Mason University.

    About Vera

    Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus. For more information, please visit www.veratx.com.

    Contacts

    Investor Contact:

    IR@veratx.com

    Media Contact:

    Greig Communications, Inc.

    Kathy Vincent

    (310) 403-8951

    kathy@greigcommunications.com

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/03a20eb6-e19f-4e90-bc8d-686494fb6681



    Primary Logo

    View Full Article Hide Full Article
  5. Completed an initial public offering with net proceeds, including the exercise of the underwriters' option in full, of approximately $48.4 million in May 2021
    - - -
    Expanded the management team to support initiation
    of atacicept clinical development program
    - - -
    Initiated Phase 2b ORIGIN clinical trial of atacicept in patients with IgA nephropathy (IgAN)

    SOUTH SAN FRANCISCO, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its financial results for the first quarter ended March 31, 2021, and provided a corporate update.

    "Over the past nine…

    Completed an initial public offering with net proceeds, including the exercise of the underwriters' option in full, of approximately $48.4 million in May 2021

    - - -

    Expanded the management team to support initiation

    of atacicept clinical development program

    - - -

    Initiated Phase 2b ORIGIN clinical trial of atacicept in patients with IgA nephropathy (IgAN)

    SOUTH SAN FRANCISCO, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its financial results for the first quarter ended March 31, 2021, and provided a corporate update.

    "Over the past nine months, we completed two capital raises for a total of approximately $128.0 million with which we have launched our clinical development program for atacicept," said Marshall Fordyce, MD, founder and chief executive officer of Vera Therapeutics. "We recently initiated the Phase 2b ORIGIN trial of atacicept to treat IgAN, which we believe could have a profound benefit for patients for whom there remains significant unmet medical need."

    First Quarter and Recent Business Highlights

    • Initiated the Phase 2b ORIGIN clinical trial, a dose-ranging study evaluating the safety and efficacy of atacicept in patients with IgA nephropathy (IgAN) who continue to have persistent proteinuria and remain at high risk of disease progression.
    • Appointed Celia Lin, MD, as Chief Medical Officer, who brings extensive clinical and industry experience in orphan diseases and multiple therapeutic areas, including nephrology and inflammation.
    • Appointed Tad Thomas, PhD, as Senior Vice President and Head of Product Development and Manufacturing to lead the Company's process development, manufacturing, analytical sciences, and quality control operations.
    • Appointed Joseph Young, MBA, as Senior Vice President of Finance and Chief Accounting Officer to oversee finance and accounting, administration, and corporate operations.
    • Completed an initial public offering with net proceeds of approximately $48.4 million, including the underwriters' exercise of their option in full, in May 2021.
    • Completed an approximately $80.0 million Series C financing in January 2021 led by Abingworth LLP. Other investors included Sofinnova Investments, Longitude Capital, Fidelity Management & Research Company LLC, Surveyor Capital (a Citadel company), Octagon Capital, Kleiner Perkins, GV (formerly Google Ventures), and Alexandria Venture Investments.

    Financial Results for the Quarter Ended March 31, 2021

    For the three months ended March 31, 2021, the Company reported a net loss of $4.7 million, or a net loss per diluted share of $12.23, compared to a net loss of $2.5 million, or a net loss per diluted share of $7.79, for the same period last year.

    During the first quarter 2021, net cash used in operating activities was $4.1 million, compared to $2.3 million for the same period last year.

    Vera reported approximately $49.5 million in cash and cash equivalents as of March 31, 2021. Subsequently, Vera completed an initial public offering of 5,002,500 shares of its Class A common stock, including the underwriters' exercise of their option in full, for net proceeds of approximately $48.4 million in May 2021.

    About Atacicept

    Atacicept is a novel, disease-modifying fully humanized fusion protein that is a dual inhibitor of the cytokines B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL). These cytokines are members of the tumor necrosis factor family that promote B-cell survival and autoantibody production associated with immunologic diseases, including IgA nephropathy (IgAN), also known as Berger's disease, and systemic lupus erythematosus. Vera believes that atacicept has the potential to be the best-in-class and the leading B cell-targeted therapy for IgAN. Atacicept has been well tolerated and has been used in clinical trials of more than 1,500 patients to date. In a clinical trial of IgAN patients, data show atacicept is the first known molecule to substantially reduce galactose-deficient immunoglobulin A (Gd-IgA1).

    About Vera

    Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus. For more information, please visit www.veratx.com.

    Forward-looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the strength of Vera's balance sheet and the adequacy of cash and cash equivalents on hand. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "plans," "will", "anticipates," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Vera's business in general, the impact of the COVID-19 pandemic, and the other risks described in Vera's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Vera undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    Contacts

    Investor Contact:

    IR@veratx.com

    Media Contact:

    Greig Communications, Inc.

    Kathy Vincent

    (310) 403-8951

    kathy@greigcommunications.com



        
    VERA THERAPEUTICS, INC.
    Unaudited Condensed Statements of Operations and Comprehensive Loss
    (in thousands, except share and per share amounts)
        
     Three Months Ended
     March 31,
      2021   2020 
    Operating expenses:   
    Research and development$2,932  $1,439 
    General and administrative 1,784   1,032 
    Total operating expenses 4,716   2,471 
    Loss from operations (4,716)  (2,471)
    Total other income (expense) 2   (3)
    Net loss and comprehensive loss$(4,714) $(2,474)
    Net loss per share attributable to common stockholders, basic and diluted$(12.23) $(7.79)
    Weighted-average shares of common stock outstanding, basic and diluted

     385,401   317,693 
        



    VERA THERAPEUTICS, INC.
    Condensed Balance Sheets
    (in thousands)
          
       March 31, December 31,
        2021   2020 
    Assets (unaudited)  
    Current assets:   
     Cash and cash equivalents$49,505  $53,654 
     Restricted cash, current 50   50 
     Prepaid expenses and other current assets 1,977   557 
      Total current assets 51,532   54,261 
    Restricted cash, noncurrent 293   293 
      Total assets$51,825  $54,554 
    Liabilities, redeemable convertible preferred stock, and stockholders' deficit  
    Current liabilities:   
     Accounts payable$1,440  $909 
     Restructuring liability, current 515   962 
     Accrued expenses and other current liabilities 1,798   535 
      Total current liabilities 3,753   2,406 
    Restructuring liability, noncurrent 1,526   1,634 
    Accrued and other noncurrent liabilities 286   286 
      Total liabilities 5,565   4,326 
    Redeemable convertible preferred stock 139,576   139,576 
    Stockholders' deficit   
     Common stock                         —                             — 
     Additional paid-in-capital 2,845   2,099 
             
     Accumulated deficit (96,161)  (91,447)
      Total stockholders' deficit (93,316)  (89,348)
      Total liabilities, redeemable convertible preferred stock, and stockholders' deficit$51,825  $54,554 
          

     



    Primary Logo

    View Full Article Hide Full Article
  6. SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021.

    Presentation details:

    Date:Friday, June 4, 2021
    Time:9:00 AM PT (12:00 PM ET)
    Presenter:Marshall Fordyce, MD, CEO and Founder of Vera

    A live webcast of the presentation can be accessed by visiting the investor relations section of the Company's website, www.veratx.com. A replay of the webcast…

    SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021.

    Presentation details:

    Date:Friday, June 4, 2021
    Time:9:00 AM PT (12:00 PM ET)
    Presenter:Marshall Fordyce, MD, CEO and Founder of Vera

    A live webcast of the presentation can be accessed by visiting the investor relations section of the Company's website, www.veratx.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation date.

    About Vera Therapeutics

    Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera's lead program is atacicept, a fusion protein that is in development for IgA nephropathy, a disease with high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept's reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). For more information please visit www.veratx.com.

    Investor Contact:

    IR@veratx.com

    Media Contact:

    Greig Communications, Inc.

    Kathy Vincent

    (310) 403-8951

    kathy@greigcommunications.com

     



    Primary Logo

    View Full Article Hide Full Article